LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

Search

Guardant Health Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

94.45 -8.56

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

93.8

Max

102.92

Pagrindiniai rodikliai

By Trading Economics

Pajamos

7.2M

-93M

Pardavimai

33M

265M

Pelno marža

-34.965

Darbuotojai

1,999

EBITDA

6.6M

-82M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+28.24% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

4.6B

14B

Ankstesnė atidarymo kaina

103.01

Ankstesnė uždarymo kaina

94.45

Naujienos nuotaikos

By Acuity

50%

50%

141 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Guardant Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-22 23:55; UTC

Rinkos pokalbiai

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

2026-02-22 23:53; UTC

Rinkos pokalbiai

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

2026-02-22 23:53; UTC

Rinkos pokalbiai

Key China Rates Likely to Be Held Steady for Now -- Market Talk

2026-02-22 23:51; UTC

Rinkos pokalbiai

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

2026-02-22 23:35; UTC

Rinkos pokalbiai

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

2026-02-22 23:21; UTC

Uždarbis

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

2026-02-22 23:20; UTC

Uždarbis

Nickel Industries 2025 Operating Profit US$126.4 Million

2026-02-22 23:19; UTC

Uždarbis

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

2026-02-22 23:19; UTC

Uždarbis

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

2026-02-22 23:18; UTC

Uždarbis

Nickel Industries Won't Pay a Final Dividend

2026-02-22 23:16; UTC

Uždarbis

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

2026-02-22 21:35; UTC

Uždarbis

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

2026-02-22 21:34; UTC

Uždarbis

Ampol Says F&I Australia, International Have Begun 2026 Strongly

2026-02-22 21:34; UTC

Uždarbis

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

2026-02-22 21:33; UTC

Uždarbis

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

2026-02-22 21:33; UTC

Uždarbis

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

2026-02-22 21:28; UTC

Uždarbis

Ampol Final Dividend A$0.60/Share

2026-02-22 21:28; UTC

Uždarbis

Ampol FY Revenue A$31.37 Billion, Down 10%

2026-02-22 21:28; UTC

Uždarbis

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

2026-02-22 21:28; UTC

Uždarbis

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

2026-02-21 14:31; UTC

Įsigijimai, susijungimai, perėmimai

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

2026-02-21 05:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-02-20 23:12; UTC

Įsigijimai, susijungimai, perėmimai

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

2026-02-20 22:12; UTC

Uždarbis

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

2026-02-20 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-20 21:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-02-20 21:23; UTC

Uždarbis

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

2026-02-20 21:20; UTC

Rinkos pokalbiai

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

2026-02-20 21:01; UTC

Įsigijimai, susijungimai, perėmimai

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

2026-02-20 20:38; UTC

Rinkos pokalbiai

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Akcijų palyginimas

Kainos pokytis

Guardant Health Inc Prognozė

Kainos tikslas

By TipRanks

28.24% į viršų

12 mėnesių prognozė

Vidutinis 132.22 USD  28.24%

Aukščiausias 175 USD

Žemiausias 110 USD

Remiantis 20 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Guardant Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

20 ratings

19

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

38.86 / 47.41Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

141 / 351 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat